Your browser doesn't support javascript.
loading
Integrative Review of Managed Entry Agreements: Chances and Limitations.
Zampirolli Dias, Carolina; Godman, Brian; Gargano, Ludmila Peres; Azevedo, Pâmela Santos; Garcia, Marina Morgado; Souza Cazarim, Maurílio; Pantuzza, Laís Lessa Neiva; Ribeiro-Junior, Nelio Gomes; Pereira, André Luiz; Borin, Marcus Carvalho; de Figueiredo Zuppo, Isabella; Iunes, Roberto; Pippo, Tomas; Hauegen, Renata Curi; Vassalo, Carlos; Laba, Tracey-Lea; Simoens, Steven; Márquez, Sergio; Gomez, Carolina; Voncina, Luka; Selke, Gisbert W; Garattini, Livio; Kwon, Hye-Young; Gulbinovic, Jolanta; Lipinska, Aneta; Pomorski, Maciej; McClure, Lindsay; Fürst, Jurij; Gambogi, Rosana; Ortiz, Carla Hernandez; Canuto Santos, Vânia Cristina; Araújo, Denizar Vianna; Araujo, Vânia Eloisa; Acurcio, Francisco de Assis; Alvares-Teodoro, Juliana; Guerra-Junior, Augusto Afonso.
Afiliação
  • Zampirolli Dias C; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Godman B; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • Gargano LP; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Azevedo PS; Health Economics Centre, University of Liverpool Management School, Liverpool, UK.
  • Garcia MM; Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Souza Cazarim M; School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa.
  • Pantuzza LLN; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Ribeiro-Junior NG; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • Pereira AL; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Borin MC; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • de Figueiredo Zuppo I; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Iunes R; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • Pippo T; Department of Pharmaceutical Sciences, Pharmacy School, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Minas Gerais, Brazil.
  • Hauegen RC; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Vassalo C; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • Laba TL; Gerência de Planejamento, Monitoramento e Avaliação Assistenciais Fundação Hospitalar do Estado de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Simoens S; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Márquez S; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • Gomez C; Graduate Program in Medicines and Pharmaceutical Services, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627. Pampulha, Belo Horizonte, 31270-901, Minas Gerais, Brazil.
  • Voncina L; SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil.
  • Selke GW; The World Bank, Washington, DC, USA.
  • Garattini L; Pan American Health Organization (PAHO), Brasília, Brazil.
  • Kwon HY; National Institute of Science and Technology for Innovation on Diseases of Neglected Populations (INCT-IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
  • Gulbinovic J; Facultad de Ciencias Médicas, Universidad Nacional del Litoral, Santa Fe, Argentina.
  • Lipinska A; Centre for Health Economics Research and Evaluation, University of Technology Sydney, Haymarket, Sydney, NSW, Australia.
  • Pomorski M; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Louvain, Belgium.
  • McClure L; Economista, Administradora de los Recursos del Sistema General de Seguridad Social en Salud (ADRES), Bogotá, Colombia.
  • Fürst J; Think Tank "Medicines, Information and Power", National University of Colombia, Bogotá, Colombia.
  • Gambogi R; Faculty of Health Studies, Rijeka, Croatia.
  • Ortiz CH; AOK Research Institute (WIdO), Berlin, Germany.
  • Canuto Santos VC; CESAV, Centre for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Ranica, Bergamo, Italy.
  • Araújo DV; Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, United Kingdom.
  • Araujo VE; College of Pharmacy, Seoul National University, Seoul, South Korea.
  • Acurcio FA; Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.
  • Alvares-Teodoro J; Agency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland.
  • Guerra-Junior AA; Agency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland.
Pharmacoeconomics ; 38(11): 1165-1185, 2020 11.
Article em En | MEDLINE | ID: mdl-32734573
ABSTRACT
BACKGROUND AND

OBJECTIVE:

Managed entry agreements (MEAs) consist of a set of instruments to reduce the uncertainty and the budget impact of new high-priced medicines; however, there are concerns. There is a need to critically appraise MEAs with their planned introduction in Brazil. Accordingly, the objective of this article is to identify and appraise key attributes and concerns with MEAs among payers and their advisers, with the findings providing critical considerations for Brazil and other high- and middle-income countries.

METHODS:

An integrative review approach was adopted. This involved a review of MEAs across countries. The review question was 'What are the health technology MEAs that have been applied around the world?' This review was supplemented with studies not retrieved in the search known to the senior-level co-authors including key South American markets. It also involved senior-level decision makers and advisers providing guidance on the potential advantages and disadvantages of MEAs and ways forward.

RESULTS:

Twenty-five studies were included in the review. Most MEAs included medicines (96.8%), focused on financial arrangements (43%) and included mostly antineoplastic medicines. Most countries kept key information confidential including discounts or had not published such data. Few details were found in the literature regarding South America. Our findings and inputs resulted in both advantages including reimbursement and disadvantages including concerns with data collection for outcome-based schemes.

CONCLUSIONS:

We are likely to see a growth in MEAs with the continual launch of new high-priced and often complex treatments, coupled with increasing demands on resources. Whilst outcome-based MEAs could be an important tool to improve access to new innovative medicines, there are critical issues to address. Comparing knowledge, experiences, and practices across countries is crucial to guide high- and middle-income countries when designing their future MEAs.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tecnologia Biomédica / Indústria Farmacêutica Tipo de estudo: Guideline / Prognostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tecnologia Biomédica / Indústria Farmacêutica Tipo de estudo: Guideline / Prognostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2020 Tipo de documento: Article